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Respiratory viral infections (RVI) are important in hematopoietic stem cell transplantations (HSCT) and
knowledge regarding incidence, morbidity, mortality, and long-term pulmonary complications is limited. We
report a study to evaluate incidence and outcomes, both short and long-term, of RVI in children receiving
HSCT. Between January 2000 and December 2012, 844 patients underwent hematopoietic stem cell trans-
plantation (HSCT) at the Hospital for Sick Children: 491 were allogeneic and 353 were autologous. When
screening for causes of death in the ﬁrst year after HSCT in the 844 patients, we found that RVI as a cause of
death was only evident in the ﬁrst 100 days after HSCT. Fifty-four (6.5%) patients were found to have an RVI
within the ﬁrst 100 days after HSCT (allogeneic ¼ 32, autologous ¼ 22). Upper and lower respiratory tract
infections were documented in 31 (57%) and 23 (43%) patients, respectively. Viruses were parainﬂuenza
(35%), respiratory syncytial virus (28%), inﬂuenza (22%), adenovirus (7%), human metapneumovirus (4%),
coronavirus (2%), and rhinovirus (2%). Three patients relapsed with their primary disease before day 100 and
were excluded. The overall mortality for the remaining 51 patients was 10% (allogeneic ¼ 4, autologous ¼ 1).
All 5 deaths were directly attributable to RVI and all 5 deaths occurred in patients with a lower respiratory
tract infection. The remaining patients were followed for a median of 4.3 years (range, 1.4 to 11.8) and no
chronic pulmonary complications were observed. A clear seasonal pattern for contracting RVI was evident
with 65% of total RVI occurring between October and March (35 of 427 versus 19 of 417, P ¼ .03). Given the
signiﬁcant mortality from RVI and the challenges in preventing them, choosing the time to start HSCT,
whenever possible, may help prevent RVI and improve outcomes.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION virus (HSV) and cytomegalovirus (CMV), were major causes
Infections are 1 of the main complications after hemato-
poietic cell transplantation (HSCT) and respiratory viral in-
fections (RVI) are being increasingly recognized as important
complications after HSCT with variable degrees of morbidity
and mortality [1-4]. In recent years, the growing number of
HSCT utilizing alternative donors and cord progenitor stem
cells, along with the common use of serotherapy, has
contributed to a signiﬁcant increase in viral infections after
HSCT [5,6]. Some well-known viruses, such herpes simplexedgments on page 1806.
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ty for Blood and Marrow Transplantation.of morbidity and mortality in HSCT [7,8]. However, since
prophylactic or preemptive anti-HSV/CMV therapy became
standard practice, morbidity and mortality from HSV or CMV
disease are rare [9,10]. Nonetheless, respiratory viruses such
as inﬂuenza, parainﬂuenza, and respiratory syncytial virus
(RSV) continue to be a major cause of morbidity and mor-
tality in patients after HSCT and there is increased awareness
for the diagnosis of these infections. However, no prophy-
lactic approach for such viruses exists in HSCT recipients.
Hence, this study’s aim was to investigate the incidence and
risk factors of RVI in children after HSCT and describe the
short- and long-term outcomes of these patients.
PATIENTS AND METHODS
This study was approved by our institutional research ethics board. The
medical records of children who received HSCT from January 2000 to
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identify those patients who had a positive test for respiratory virus obtained
by nasopharyngeal aspirate (NPA), bronchoalveolar lavage (BAL), pleural tap,
or lung biopsy specimen. Microbiological testing included the following
methodologies: (1) virus isolation in cell culture (2000 to 2007 for NPA and
2000 to 2011 for BAL and biopsies) for inﬂuenza A and B, RSV, parainﬂuenza
virus 1 through 3, and adenovirus; (2) direct ﬂuorescent antibody testing
(2000 to 2012) on all NPAs, bronchoscopic BALs for 8 viruses (inﬂuenza A
and B, RSV, parainﬂuenza virus 1 through 3, adenovirus, and human
metapneumovirus (hMPV); (3) PCR for thepandemic inﬂuenza strain (May to
December 2009); (4) PCR for adenovirus (2002 to 2012); and (5) multiplex
PCR (May 2011 to December 2012) for inﬂuenza A and B, RSV, parainﬂuenza
virus 1 through 4, adenovirus, hMPV, enterovirus, rhinovirus, bocavirus, and
coronaviruses. Data collected included patient demographics, indication for
HSCT, type of transplantation (allogeneic or autologous), graft type, condi-
tioning regimen, donor details for allogeneic patients, graft-versus-host
disease (GVHD) prophylaxis, time from HSCT to positive respiratory virus
result, clinical course, transplantation-related mortality (TRM) and cause,
long-term pulmonary complications, and overall survival.
Deﬁnitions
The following deﬁnitions were used in the study. An upper respiratory
tract infection (URTI) was deﬁned as detection of an RVI from upper res-
piratory secretions together with symptoms from the upper respiratory
tract (nose and throat). A lower respiratory tract infection (LRTI) was deﬁned
as either hypoxia or pulmonary inﬁltrates together with identiﬁcation of an
RVI in upper respiratory secretion, BAL, pleural tap, or lung biopsy. The day
of engraftment was deﬁned as the ﬁrst of 3 consecutive days in which the
peripheral absolute neutrophil count was > .5  109/L. TRM was deﬁned as
being either due to an RVI or other transplantation toxicities. Death due to
RVIwas deﬁned as death from respiratory failure with no other cause of the
pneumonia. Long-term pulmonary complication was deﬁned as any limita-
tion of pulmonary status, including pulmonary function tests. Relapse was
deﬁned by the ﬁnding of hematologic or cytogenetic recurrence or by the
initiation of therapy for recurrence. Progressive disease was deﬁned as tu-
mor growth of more than 20% or spreading since undergoing trans-
plantation [11].
Supportive Care
All patients were nursed in protective isolation in single rooms with
high-efﬁciency particulate air ﬁlters. All patients had indwelling central
venous catheters and the majority received nutritional support with naso-
gastric feeding or total parenteral nutrition. Infection prophylaxis included
ﬂuconazole for fungal prophylaxis, ganciclovir for CMV prophylaxis (2000 to
2005), and preemptive strategy from 2005 onwards. Growth factors were
given as indicated, and laminar air ﬂow rooms were used from day 0 until
engraftment. Intravenous immunoglobulin at a dose of .5 g/kg was supple-
mented if the IgG level was less than 400 mg/dL. The IgG level was routinely
monitored every week in all patients. Pneumocystis jiroveci prophylaxis was
given before HSCT and after HSCT for at least 6 months. Pneumococcal pro-
phylaxis with penicillin continued for at least 1 year or until the adminis-
tration of pneumococcal vaccine. Blood products were transfused to
maintain hemoglobin concentration > 70 mg/L and platelet counts of
20,000/mm3. Fever during the neutropenic phase was treated with broad-
spectrum antibiotics and amphotericin or caspofungin, as necessary, and
modiﬁed subsequently according to the results of blood or tissue cultures.
Clinical Follow-Up
Patients received their preparatory regimen, underwent trans-
plantation, and recovered in the hospital, where they were examined by the
medical team twice each day until they achieved engraftment. All patients
with respiratory symptomswere investigated for the presence of respiratory
viruses. Chest radiographs and computed tomography scans were obtained
if clinically indicated. NPAs, throat swaps, or nasal swabs were used for
obtaining upper respiratory specimens. BAL or pleural tap and/or lung bi-
opsy were used for obtaining lower respiratory specimens.
Endpoints
The primary endpoint of the study was to review all RVI-positive pa-
tients after HSCT and describe their outcome in terms of TRM and long-term
pulmonary complications.
Statistics
Univariate logistic regression models were constructed to analyze the
impact of risk factors on TRM within the ﬁrst 100 days, including trans-
plantation type (allogeneic versus autologous), graft type (bone marrow
versus peripheral blood stem cells versus cord blood), utilization of sero-
therapy (antithymocyte globulin, Alemtuzumab [MabCampath; GenzymeCanada Inc., Mississauga, Ontario], and no serotherapy), and underlying
disorder (malignant versus benign). All reported P values were 2-sided, and
a signiﬁcance level of .05 was used. All statistical analyses were carried out
using SPSS version 12.5.
RESULTS
Eight hundred forty-four patients underwent HSCT at the
Hospital for Sick Children, Toronto, Canada during the study
period and comprise the study population. The transplant
recipients consisted of 341 female and 503 male patients,
with a median age of 7.5 years (range, 1 month to 17.8 years).
The HSCT was allogeneic in 491 patients and autologous in
353 patients. The diseases for which HSCT was performed
were acute lymphoblastic leukemia (n ¼ 138), acute myeloid
leukemia (n ¼ 110), myelodysplastic syndrome (n ¼ 21),
severe aplastic anemia (n ¼ 49), inherited marrow failure
(n ¼ 29), primary immune deﬁciency (n ¼ 58), non-Hodgkin
lymphoma (n ¼ 44), Hodgkin disease (n ¼ 28), chronic my-
elogenous leukemia (n ¼ 16), metabolic diseases (n ¼ 25),
hemophagocytic lymphohistiocytosis (n ¼ 17), brain tumors
(n ¼ 103), solid tumors (n ¼ 179), thalassemia (n ¼ 15), and
others (n ¼ 12).Incidence of RVI
During the study period and among the 844 HSCT re-
cipients, 96 patients with RVI were documented. Screening
for causes of death in the 96 patients, we found that RVI was
never the cause of death after day 100 after HSCT. In the ﬁrst
100 days after HSCT, there were 54 patients with RVI. As
these 54 patients were the focus of the study, their diagnosis
and conditioning regimen including use of serotherapy are
described in Table 1. Only 1 patient with diagnosis of severe
combined immune deﬁciency (SCID)/Omenn’s syndrome
received conditioning with busulfan and cyclophosphamide.
The remaining 5 SCID patients did not receive any condi-
tioning regimen. When analyzing utilization of serotherapy,
we found 11 patients who received antithymocyte globulin
and 1 who received alemtuzumab.
The overall frequency of documented RVI in the ﬁrst
100 days after HSCT was 6.4%. The frequency was slightly
higher in allogeneic (6.5%) than in autologous (6.2%) trans-
plantations (P ¼ .867). Twenty-three patients had LRTI: 17
occurring in allogeneic patients and 6 in autologous HSCT
patients. The frequency of a LRTI was 3.5% in allogeneic and
1.7% in autologous HSCT patients. Nineteen patients had
parainﬂuenza infections (11 allogeneic, 8 autologous). Six
patients had LRTI and 13 patients had URTI. The median
time to diagnosis of parainﬂuenza infection was 25 days
(range, 1 to 81 days) after HSCT. One patient with LRTI was
treated was with ribavirin. Fifteen patients had RSV infec-
tion (9 allogeneic, 6 autologous). Eight had LRTI and 7 had
URTI. The median time to diagnosis of RSV infection was
14 days (range, 1 to 52 days) after HSCT. Six patients with
LRTI were treated with ribavirin immediately after RSV was
identiﬁed. Health Canada approved palivizumab (RSV Ig) in
2012 and only 1 patient received it. Twelve patients had
inﬂuenza infection (7 allogeneic, 5 autologous). Eight pa-
tients had inﬂuenza A and 4 had inﬂuenza B. Four patients
had LRTI and 8 patients had URTI. The median time to
diagnosis of inﬂuenza infection was 31 days (range, 1 to
100 days) after HSCT. All 12 patients received oseltamivir.
Four patients had adenovirus infections (3 allogeneic, 1
autologous) proven by adenovirus PCR positive from BAL or
pleural ﬂuid and/or lung biopsy. All of them had LRTI and
subsequently developed respiratory distress. The median
Figure 1. Seasonal pattern of 54 patients with RVI.
Table 1
Characteristics of Patients with Identiﬁed Respiratory Virus Infections
Characteristic Value
Age, median (range) 7.5 yr (1 mo-17.8 yr)
Diagnosis
Malignant disorders 38
Neuroblastoma 12
Acute lymphoblastic leukemia 6
Acute myeloid leukemia 6
Medulloblastoma 5
Hemophagocytic lymphohistiocytosis 3
Non-Hodgkin lymphoma 1
Hodgkin lymphoma 1
MDS 1
Atypical rhabdoid/teratoid tumor 1
Pineoblastoma 1
Ependymoblastoma 1
Benign disorders 16
SCID 6
Severe aplastic anemia 3
Wiskott Aldrich syndrome 3
Thalassemia 1
Sickle cell disease 1
Hurler’s syndrome 1
Fanconi’s anemia 1
Type of transplant
Allogeneic 32
HLA-identical sibling 14
Family mismatch 1
Unrelated donor 17
Autologous 22
Conditioning regimen
TBI þ chemotherapy 6
Chemotherapy alone 43
No conditioning regimen 5
Serotherapy 12
ATG 11
Alemtuzumab 1
None given 42
Graft type
Bone marrow 25
Peripheral blood stem cells 22
Cord blood 7
Type of viral infection
Parainﬂuenza 19
RSV 15
Inﬂuenza A 8
Inﬂuenza B 4
Adenovirus 4
hMPV 2
Rhinovirus 1
Coronavirus 1
MDS indicates myelodysplastic syndrome; TBI, total body irradiation; ATG,
antithymocyte globulin.
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(range, 8 to 100 days) after HSCT. All patients with adeno-
virus received cidofovir therapy. The remaining 4 patients
(2 allogeneic, 2 autologous) were documented to have
hMPV (2 patients), coronavirus (1 patient) and rhinovirus
infections (1 patient). Of the 32 patients who received
allogeneic HSCT, 12 were receiving therapy for acute GVHD
grade II to IV. The number of patients who contracted RVI
and the type of viruses are summarized in Table 1. The
seasonal pattern of RVI is shown in Figure 1, with the
number of patients who contracted RVI in each month
displayed. Thirty-ﬁve of the 54 total RVI were contracted
between October and March, which is the high ﬂu season in
Canada. with March being the worst month. Comparing
positive RVI patients versus negative patients, there was a
statistically signiﬁcant difference for contracting RVI in the
high season versus the low season (35 of 427 versus 19 of
417, P ¼ .03).Outcome of RVI in the First 100 Days after HSCT
Eleven patients required mechanical ventilation (para-
inﬂuenza, 4; inﬂuenza, 3; RSV, 2; adenovirus, 2). Four allo-
geneic and 1 autologous HSCT recipients died within
100 days after transplantation because of the RVI and all of
them were mechanically ventilated. Thus, the overall mor-
tality was 10.0% (13.3% allogeneic and 4.8% autologous,
P ¼ .304). None of the 4 allogeneic transplant recipients who
died had acute GVHD. Two of the 19 patients with para-
inﬂuenza infections died (1 patient was treated with riba-
virin). Two additional patients with parainﬂuenza infection
died; 1 from liver veno-occlusive disease and another from
pulmonary hypertension. Thus, the mortality caused by
parainﬂuenza was 10.5% and the total mortality with a
diagnosis of parainﬂuenza was 21%. For those with adeno-
virus respiratory infection (n ¼ 4), 2 patients died of
adenovirus infections. The mortality caused by adenovirus
infection was 50%. One of 15 patients died of RSV infection.
The mortality caused by RSV infection was 6.7% and that
patient was treated with ribavirin. None of 12 patients with
inﬂuenza, hMPV, coronavirus, and rhinovirus infections died
from respiratory complications. After day 100 after HSCT, 3
more patients died from TRM but death was not related to
respiratory problems. The remaining 43 patients were fol-
lowed for amedian of 4.3 years (range,1.4 to 11.8). No chronic
pulmonary complication or allo-immune lung syndromewas
observed.Details of Patients Who Died from RVI (Table 2)
Parainﬂuenza
Two patients died from parainﬂuenza LRTI. A 1-year-old
patient with Wiskott-Aldrich syndrome who underwent
unrelated cord blood transplantation developed respira-
tory distress on day 24 after transplantation. NPA was
positive for parainﬂuenza type 3 antigen. Ribavirin, nitric
oxide, and high-frequency oscillator support were given.
The second patient was a 2-year-old boy with diagnosis of
relapse acute myeloid leukemia who underwent matched
sibling bone marrow transplantation. Parainﬂuenza type 1
antigen was positive from NPA on day 19 after HSCT. This
patient developed acute respiratory distress syndrome
(ARDS) with radiographic ﬁndings consistent with
pneumonitis.
RSV
A 2-month-old patient with diagnosis of SCID with
Omenn’s syndrome underwent matched sibling bone
marrow transplantation. This patient developed ARDS from
RSV pneumonitis on day 11 after HSCT.
Table 2
Details of Patients who Died from RVI after HSCT
Diagnosis Age at
HSCT
Conditioning Regimen Stem Cell Respiratory
Viruses
Interval,
HSCT to
Infection
Cause of Death
Severe aplastic anemia 11 yr Fludarabine/cyclophosphamide/ATG Unrelated cord 5/6 Adenovirus 98 d Pneumonitis, ARDS
Neuroblastoma, stage 4 18 mo Carboplatin/etoposide/melphalan Autologous Adenovirus 21 d Pneumonitis, ARDS
SCID 2 mo Busulfan/cyclophosphamide Matched sibling BM RSV 11 d Pneumonitis, ARDS
Relapsed AML 2 yr Busulfan/cyclophosphamide Matched sibling BM Parainﬂuenza
type 1
19 d Pneumonitis, ARDS,
pulmonary hypertension
Wiskott-Aldrich syndrome 1 yr Busulfan/cyclophosphamide/ATG Unrelated cord 6/6 Parainﬂuenza
type 3
24 d Pneumonitis, ARDS,
pulmonary hypertension
AML indicates acute myeloid leukemia; BM, bone marrow.
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Two patients died from adenovirus pneumonitis and
ARDS. An 18-month-old patient with diagnosis of neuro-
blastoma stage 4 underwent autologous HSCT after high-
dose chemotherapy. This patient had delayed engraftment
and developed ARDS, which was positive for adenovirus
from BAL and pleural ﬂuid. Another patient was an 11-year-
old boy who underwent unrelated cord blood trans-
plantation for severe aplastic anemia. This patient had
primary graft failure, subsequently developed respiratory
distress, and required high-frequency oscillation. Adenovirus
was positive from BAL and lung biopsy.
Univariate Analysis
Type of transplantation, graft type, utilization of sero-
therapy, and underlying malignant disorder were analyzed
using univariate analysis. None of these factors were signif-
icantly correlated with TRM (type of transplantation [P ¼
.347], graft type [P ¼ .213], serotherapy [P ¼ .405], and un-
derlying malignant disorder [P ¼ .156]).
DISCUSSION
In this large pediatric study, we found that 6.5% of pa-
tients receiving allogeneic or autologous HSCT had a positive
RVI that led to 10% overall mortality in the ﬁrst 100 days after
HSCT. Mortality was higher for allogeneic recipients: 13.3%
compared with 4.8% for autologous recipients. Furthermore,
for a median follow-up of 4.3 years (range, 1.4 to 11.8) pa-
tients who tested positive for respiratory virus but did not
die had no long-term pulmonary complications and patients
who contracted the virus after 100 days after HSCT did not
have an adverse event.
The total incidence of RVI in this study was consistent
within the range of 5% to 11% by previous published data of
pediatric HSCT recipients [12,13]. However, our study
particularly reported the incidence of RVI within the ﬁrst
100 days after transplantation, as it is a very distinct pattern
in our population and different from aforementioned studies.
Our data showed that RVI episodes were clustering within
the ﬁrst 100 days after transplantation. Only 1 patient
developed inﬂuenza A URTI at 5 months after HSCT but no
serious respiratory complication was observed. Similar to
patients who were diagnosed with URTI and LRTI after
6 months after HSCT, none had prolonged admission or died
from respiratory illnesses.
We supplemented our routine viral respiratory di-
agnostics with PCR testing (adenovirus PCR, pandemic
inﬂuenza PCR, multiplex respiratory PCR), if requested by the
treating physician. PCR has been proven to be amore speciﬁc,
sensitive, and rapid method for detecting respiratory virusescompared with antigen testing and viral culture and was
likely responsible for increasing our rates of detection,
though changes in methodology over the study time frame
mean that testing algorithms were applied differently as
testing methodologies changed [14-16].
Even with a lower incidence of adenovirus compared
with parainﬂuenza and RSV infections in this study, the
respiratory-related mortality was higher for adenovirus, ie,
50%. All 4 patients were conﬁrmed to have a positive
adenovirus PCR from either BAL or pleural ﬂuid and lung
biopsy after diagnosis of LRTI. Moreover, 2 patients who died
from severe pneumonitis and ARDS with a positive adeno-
virus PCR test did not have another apparent cause of res-
piratory illness. It was described that disseminated
adenovirus infection can cause pulmonary consolidation,
such as bacterial pneumonia [17,18]. Because of similar
clinical and radiographic ﬁndings, adenovirus infection may
be under-recognized as a cause of fatal pneumonia in
immunocompromised patients with severe lymphopenia or
lymphocyte dysfunction. Likewise, our 2 patients with
adenovirus infection both had delayed engraftment.
Adenovirus infection is associated with high mortality, up
to 100% in the pediatric HSCT [19-21]. Routinemonitoring for
adenoviremia is recommended after HSCT because of
asymptomatic reactivation in most cases [22]. Cidofovir is
widely used for both preemptive and therapeutic treatment
of adenovirus infection despite well-recognized toxicities
[23,24]. Identiﬁcation of patients at risk of adenovirus
infection is very crucial, as immune reconstitution is a key
factor for reactivation. Rapid withdrawal of immunosup-
pressive medications should also be considered whenever
possible [25].
Respiratory-related mortality from parainﬂuenza virus in
this study is lower, 10.5%, than in other studies, which
showed approximately 30% to 70%. This could be explained
by very early years when transplantations were completed
and the mainly adult study population in previous reports
[26-29]. A large retrospective cohort study from Fred
Hutchinson Cancer Research Center described unrelated
transplantation as the major risk factor for parainﬂuenza
virus acquisition as well the use of high-dose corticosteroids
[29]. For our 2 patients who died from parainﬂuenza virus
pneumonia, 1 with diagnosis of Wiskott-Aldrich syndrome
received methylprednisolone as GVHD prophylaxis for an
unrelated cord blood transplantation. However, another pa-
tient with relapsed acute myeloid leukemia did not develop
GVHD or receive any corticosteroids treatment. Aerosolized
ribavirin was given to the ﬁrst patient but it was given later
during the course of pneumonia. The beneﬁt of using aero-
solized ribavirin in the treatment of parainﬂuenza
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The early diagnosis of parainﬂuenza infection could expedite
ribavirin treatment initiation and improve the outcome [25].
The incidence of RSV infection in this study was 28% and
LRTI composed more than one half of all RSV infections.
Interestingly, the mortality is only 6.7%, which is lower than
20% to 40% in other studies in HSCT recipients [1]. Treatment
with aerosolized ribavirin in 6 of 7 patients with RSV LRTI
may potentially be the reason for lowered mortality,
although 1 fatal case was observed after the patient received
ribavirin. HSCT recipients have high potential for progression
from URTI to severe LRTI without well-deﬁned and speciﬁc
risk factors for death [4,30,31]. A pooled analysis by Shah and
Chemaly suggested that ribavirin treatment with/without
RSV-speciﬁc immunoglobulin or palivizumab had lower
rates of mortality by almost one-third in a review of 21
separate studies [32]. Another small retrospective analysis of
palivizumab given for RSV URTI did not show protective ef-
fect of progression to LRTI [33-35].
No death associated with inﬂuenza, hMPV, rhinovirus,
and coronavirus infections was observed in this study. High
mortality between 15% and 70% has been reported in HSCT
recipients with inﬂuenza infection, but recent data showed
an improvement with the availability of neuraminidase in-
hibitors [36,37]. An inactivated vaccine is the only prophy-
lactic approach for inﬂuenza infection, but it appears to be
less effective in HSCT recipients, particularly in the ﬁrst few
months after transplantation, as well as in patients who
required immunosuppressive agents for GVHD treatment
[38-41]. However, the inﬂuenza vaccine is considered to be
safe as no major local or general adverse effects were re-
ported after use in transplant recipients [42]. hMPV infection
has been reported with an incidence of 3% to 9% in adult
HSCT recipients and patients with hematologic malignancies.
hMPV may be associated with severe pneumonia and fatal
lower -respiratory tract disease in HSCT recipients [43]. Even
though hMPV infections are documented in asymptomatic
cases [44], further analysis of a larger number of patients is
necessary to identify its real impact in after transplantation
population. For human rhinovirus and coronavirus, despite
the high incidence of infections among HSCT recipients,
morbidity and mortality are both relatively low. Asymp-
tomatic detections are common, accounting for 13% and 41%
of patients with rhinovirus and coronavirus, respectively
[45].
Mortality is higher in allogeneic HSCT and recipients of
cord blood transplants. However, no signiﬁcant difference
was observed by univariate analysis. Previous studies
revealed GVHD and use of immunosuppressive agents as
major risk factors associatedwith LRTI andmortality [46-48].
Because of the small number of patients who developed
GVHD in our study, logistic regression analysis could not be
performed. Likewise, various conditioning regimens were
used in our 5 patients who died from RVI. We are unable to
establish the correlation between transplantation type and
respiratory viruseassociated death.
The strength of our study is in the large number of pa-
tients examined from a single center with a uniform isolation
practice, contact precautions, and supportive care. The lim-
itation is in the retrospective nature of the study design.
Nonetheless, with an incidence of 6.5% among HSCT re-
cipients, prospective studies could be a challenge and when
using multiple centers, another challenge arises in terms of
isolation practices, infection precautions, and supportive
care heterogeneity among HSCT centers.Finally, given the high mortality that is associated with
viral infections in the ﬁrst 100 days after HSCT in our study, it
may be intuitive to avoid admission of patients in the high
season for respiratory viruses, especially in a country such as
Canada where there is a signiﬁcant difference between
summer and winter temperatures. In Canada, the high sea-
son for respiratory viral infections span between October and
March and in our study, 35 patients (65%) contracted RVI
during the high season, compared with 19 patients (35%) in
the remaining months. This may not be feasible for children
who need their HSCT urgently, for example those with
aggressive leukemia, but may be appropriate for those with
elective nonmalignant HSCT to minimize their risk of
acquiring these infections early after HSCT.ACKNOWLEDGMENTS
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